How a $110 Million Loan Fuels the Next Wave of European HealthTech

Jan de Vries · 2026-08-31

Let's talk about what's really happening in European HealthTech. It's not just another funding round—it's a strategic move that could reshape how we treat some of the most challenging medical conditions. Stockholm-based Elekta just secured a major financial boost, and the implications reach far beyond their Swedish headquarters. They've landed a loan worth up to $110 million from the European Investment Bank (EIB). That's the EU's financing arm, and they don't just write checks to anyone. This tells you something about where Europe is placing its bets for the future. ### Why This Financing Matters More Than The Money Sure, $110 million is a significant amount. But here's the thing—it's part of the EIB's TechEU programme. Think of that as Europe's answer to staying competitive in critical tech sectors. The goal? To make sure innovation doesn't just happen, but happens here. Karl Nehammer, Vice-President at the EIB, put it bluntly: "Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here." He's right. This financing isn't about keeping the lights on. It's about powering the next generation of cancer and neurological treatments. The loan actually covers about half of Elekta's massive $220 million research program scheduled for 2026 through 2029. Most of that work will happen in Sweden and the Netherlands, keeping that expertise firmly planted in European soil. ### The Company Behind The Headlines You might not know Elekta by name, but you should. Founded back in 1972 by Lars and Laurent Leksell and now publicly traded, they've been quietly revolutionizing radiation medicine for decades. Their technology treats more than 2 million patients every single year. Let that sink in—two million people. Their focus is precision. We're talking about adaptive radiotherapy, software-driven treatment planning, and clinical workflows that actually work for doctors and patients. They tackle some of the toughest cancers out there: - Brain tumours - Breast cancer - Kidney and lung cancers - Pancreatic and prostate cancers But here's what's interesting—they're not stopping at cancer. Their work extends to neurological disorders too, which is where this new funding gets really exciting. ### Where The Money Is Actually Going Klara Eiritz, Elekta's CFO, explained the need perfectly. "As demand for cancer care continues to grow, healthcare providers are looking for solutions that help them treat more patients while maintaining quality and precision." That's the challenge, isn't it? Scaling care without sacrificing outcomes. This financing gives them flexibility. It backs their work across several key areas: - Radiotherapy and radiosurgery - Brachytherapy (that's internal radiation therapy) - The software platforms that plan and deliver these complex treatments The aim is straightforward but ambitious: make treatments more accurate and efficient so healthcare providers can help more people. They're targeting improvements for conditions like brain and body tumours, essential tremor, and certain forms of epilepsy. ### The Bigger Picture For European HealthTech This isn't happening in a vacuum. The EIB Group signed a staggering $110 billion in new financing across more than 870 projects in 2025 alone. They're putting serious money behind climate action, digitalization, security, and—crucially—social infrastructure like healthcare. Elekta's deal follows other recent EIB moves in HealthTech, including a $22 million venture debt agreement with Finnish digital pathology firm Aiforia last July. There's a pattern here. Europe is building its health technology ecosystem deliberately, with the EIB acting as both banker and strategic partner. Elekta now employs about 4,000 people with offices in over 40 countries, selling into more than 120 markets worldwide. They're already a global player. This funding isn't about survival—it's about acceleration. It's about maintaining that European edge in medical technology when competition has never been fiercer. So when you see headlines about another European tech loan, look deeper. This is about where treatments for cancer and neurological disorders will come from in the next decade. It's about whether Europe remains a leader or becomes a follower in one of the most important industries we have. Based on this move, they're planning to lead.